Overview

First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2027-05-01
Target enrollment:
Participant gender:
Summary
The goal of the study is to investigate of the prognostics and predictive role of TUBB3 expression in locally advanced breast cancer
Phase:
PHASE2
Details
Lead Sponsor:
The National Center of Oncology, Azerbaijan
Treatments:
Cisplatin
Cyclophosphamide
Doxorubicin
Gemcitabine
Paclitaxel